This study analyzed the clinical outcomes of redo surgical aortic valve replacement (AVR) for prosthetic valve failure from 2010 to 2021 across four tertiary centers, involving 324 patients. The primary focus was on operative mortality, with secondary outcomes including overall survival, cardiac death, and aortic valve-related events. The findings revealed that redo AVR poses a relatively high risk, particularly in patients with endocarditis, resulting in a 4.6% overall operative mortality. However, for patients without endocarditis, the operative mortality decreased significantly to 2.5%. Risk factors identified for operative mortality included endocarditis, longer cardiopulmonary bypass time, and lower left ventricular ejection fraction. The study concludes that redo AVR offers excellent outcomes for patients without endocarditis, especially those with acceptable left ventricular ejection fraction.